Which peptide drugs are in FDA shortage?
Live from the FDA shortage database — and what each shortage means for legal compounding.
Short answer: As of September 21, 2026, 12 peptide and peptide-derived drugs appear on the FDA drug shortage list: 14 entries are an active (current) shortage and 25 are listed as to be discontinued. Shortage status matters legally because a drug in shortage may be compounded in ways it cannot be once the shortage resolves.
12drugs affected
14current
25to be discontinued
GLP-1 and metabolic peptides
Liraglutide 9 current 2 to be discontinued
Current
Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)
Current
Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)
Current
Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)
Current
Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)
Current
Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)
Estimated shortage duration: TBD
Current
Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)
Distributed by Teva
To Be Discontinued
Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)
Product will be available until discontinuation in January 2027; Discontinuation of the manufacture of the drug
Current
Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)
Product will be available until discontinuation in January 2027
Current
Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)
Distributed by Teva
Current
Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)
Estimated shortage duration: TBD
To Be Discontinued
Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46)
Discontinuation of the manufacture of the drug
Insulin 7 to be discontinued
To Be Discontinued
Humalog Mix 75/25, Injection, 100 [iU]/1 mL (NDC 0002-8233-05)
A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance.
To Be Discontinued
Rezvoglar, Injection, 100 [iU]/1 mL (NDC 0002-8980-05)
A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance.
To Be Discontinued
Insulin Lispro Junior KwikPen, Injection, 100 [iU]/1 mL (NDC 0002-7752-05)
A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance.
To Be Discontinued
Lyumjev, Injection, U-100 Tempo Pen Sample (NDC 0002-8235-99)
A business decision was made to discontinue manufacture of the drug.
To Be Discontinued
Lyumjev, Injection, U-100 Tempo Pen (NDC 0002-8235-05)
A business decision was made to discontinue manufacture of the drug.
To Be Discontinued
Humalog, Injection, U-100 Tempo Pen (NDC 0002-8213-05)
A business decision was made to discontinue manufacture of the drug.
To Be Discontinued
Basaglar, Injection, U-100 Tempo Pen (NDC 0002-8214-05)
A business decision was made to discontinue manufacture of the drug.
Semaglutide 3 to be discontinued
To Be Discontinued
Rybelsus, Tablet, 3 mg (NDC 0169-4303-30)
Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
To Be Discontinued
Rybelsus, Tablet, 14 mg (NDC 0169-4314-30)
Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
To Be Discontinued
Rybelsus, Tablet, 7 mg (NDC 0169-4307-30)
Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
Pramlintide 2 to be discontinued
To Be Discontinued
SymlinPen® 60 , Injection, 1000 ug/1 mL (NDC 0310-6615-02)
Discontinuation of the manufacture of the drug.
To Be Discontinued
SymlinPen® 120 , Injection, 1000 ug/1 mL (NDC 0310-6627-02)
Discontinuation of the manufacture of the drug.
Hormone and endocrine peptides
Desmopressin 4 current
Current
Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)
Current
Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)
Estimated recovery: TBD
Current
Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)
Estimated recovery: TBD
Current
Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)
Estimated recovery: TBD
Somatropin 1 to be discontinued
To Be Discontinued
Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21)
Discontinuation of the manufacture of the drug
Other therapeutic peptides
Icatibant 2 to be discontinued
To Be Discontinued
Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-86)
Discontinuation of the manufacturer of the drug
To Be Discontinued
Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-93)
Discontinuation of the manufacturer of the drug
Peptide antibiotics and antifungals
Bacitracin 1 current
Current
Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)
Shortage is estimated for 24 months
Caspofungin 3 to be discontinued
To Be Discontinued
Caspofungin Acetate, Injection, 5 mg/1 mL (NDC 0781-3421-94)
Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug
To Be Discontinued
Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 0781-3423-94)
Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug
To Be Discontinued
Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 63323-358-10)
Discontinuation of the manufacture of the drug
Daptomycin 2 to be discontinued
To Be Discontinued
Daptomycin, Injection, 500 mg/10 mL (NDC 57884-3151-1)
Discontinuation of the manufacture of the drug
To Be Discontinued
Daptomycin, Injection, 500 mg/10 mL (NDC 0143-9378-01)
Discontinuation of the manufacture of the drug; Marketed by Hikma Pharmaceuticals USA, Inc.
Micafungin 2 to be discontinued
To Be Discontinued
Micafungin Sodium, Injection, 10 mg/1 mL (NDC 42023-229-10)
A business decision was made to discontinue manufacture of the drug.
To Be Discontinued
Micafungin Sodium, Injection, 20 mg/1 mL (NDC 42023-230-10)
A business decision was made to discontinue manufacture of the drug.
Vancomycin 1 to be discontinued
To Be Discontinued
Vancomycin Hydrochloride, Injection, 10 g Vial NovaPlus (NDC 0409-5017-01)
Discontinuation of the manufacture of the drug
Why shortage status decides whether compounding is legal
A drug shortage is not just a supply problem — it changes what compounding pharmacies may lawfully make. Normally a compounder may not produce a drug that is "essentially a copy" of a commercially available FDA-approved product. That restriction does not apply while the drug sits on the FDA shortage list, which is why compounded GLP-1s were legal during the semaglutide and tirzepatide shortages and became violations once FDA declared those shortages resolved.
What is permitted during a shortage
- 503A pharmacies may compound the drug against a valid prescription
- 503B outsourcing facilities may produce it for healthcare facilities
- The "essentially a copy" restriction is waived for the drug in shortage
What is still required
- Proper pharmacy or outsourcing-facility licensing
- Quality and safety standards, including appropriate ingredient sourcing
- Accurate labeling
What happens when the shortage ends
- FDA publishes notice that the shortage is resolved
- Compounders must stop producing copies of the drug
- A transition period may apply, after which patients move back to the commercial product
What to do during a shortage
For patients
- Contact your pharmacy about availability and check more than one
- Ask your prescriber about therapeutic alternatives
- Ask whether a legally compounded option applies to your drug
- Do not stop a prescribed medication without medical guidance
For healthcare providers
- Monitor FDA shortage notifications for status changes
- Identify therapeutic alternatives before supply runs out
- Confirm a drug is still listed in shortage before relying on compounded supply
Frequently asked questions
Which peptide drugs are currently in FDA shortage?
As of September 21, 2026, 12 peptide and peptide-derived drugs appear on the FDA drug shortage list: 14 entries are an active (current) shortage and 25 are listed as to be discontinued. Shortage status matters legally because a drug in shortage may be compounded in ways it cannot be once the shortage resolves.
Can a peptide be legally compounded during an FDA shortage?
Yes. While an FDA-approved drug is on the FDA shortage list, 503A pharmacies and 503B outsourcing facilities may compound versions of it because the "essentially a copy of a commercially available drug" restriction does not apply to a drug in shortage. Once FDA declares the shortage resolved, that permission ends and compounders must stop producing copies.
Why did compounded semaglutide and tirzepatide become illegal?
Compounded semaglutide and tirzepatide were lawful only because both drugs sat on the FDA shortage list. When FDA declared those shortages resolved, the shortage-based exception that permitted compounding disappeared, and compounding copies of them became an "essentially a copy" violation.
How often is this peptide shortage list updated?
This page is regenerated automatically from the openFDA drug shortage API, so it reflects FDA's published shortage records rather than a manually maintained list, and was last refreshed on September 21, 2026.
Important: Shortage status can change between refreshes, and FDA's database is the authoritative record. Verify current status on the FDA Drug Shortage Database before making a clinical or compliance decision. This page is informational and is not legal or medical advice.